BC Platforms, a proud founding member of ARTEMIs, is excited to attend the 2024 Consortium Meeting in Barcelona with its fellow participants.
ARTEMIs is a 4-year project launched on January 2024, to advance the management of MAFLD, Europe’s leading cause of chronic liver disease (CLD). ARTEMIs aims to control this fast-growing metabolic syndrome and its complications by leveraging advanced liver and heart Virtual Twins. The project will co-design, develop, and evaluate a clinical decision support system (CDSS) for managing MAFLD patients.
ARTEMIs is funded by the European Union under the Horizon Europe program, grant agreement N° 101136299.
We are proud to attend and speak at the 2nd edition of Industry Symposium on “AI in the Life Sciences”! This event brings together experts to explore translational AI research that is clearly relevant to application in the Life Sciences industries, namely the pharmaceutical industry, but also the biotech and medtech industries. Come heart our CSO
We are proud to partner in the upcoming 13th IMPACCT Real World Evidence US Summit! The Summit brings together industry leaders in RWE and Evidence Generation to explore the latest innovations in utilizing real-world data across the drug development lifecycle. The summit offers a unique opportunity to discuss key strategies for enhancing RWE with AI,
BC Platforms is excited to attend the 2025 EUCAIM events to join forces in advancing AI-powered imaging to save lives. The event agenda includes the EUCAIM Consortium Meeting, European Cancer Imaging Initiative event, and EUCAIM Workshops. Read more about the event here.
